Skip to content

Experimental characterization of a diamond detection system for combined dose, LET and RBE assessment in clinical proton beams

MetadataDetails
Publication Date2025-09-25
JournalPhysics in Medicine and Biology
AuthorsC. Verona, Andrea Fabbri, A. Fazzi, Lucrezia Bianchi, Anna Bianchi
InstitutionsIstituto Nazionale di Fisica Nucleare, Istituto Nazionale di Fisica Nucleare, Trento Institute for Fundamental Physics And Applications
AnalysisFull AI Review Included
  • Innovation: First experimental validation of the DIODE detector, a novel device embedding a single-crystal diamond (SCD) Schottky diode dosimeter (Dos) and a microdosimeter (µDos) within a single compact housing, enabling simultaneous dose, LET, and RBE measurement in clinical proton beams.
  • Method: Tested under a 70 MeV monoenergetic proton beam at the Trento Proton Therapy Centre; benchmarked against EBT3 radiochromic films (dosimetry) and a mini-TEPC (microdosimetry), with Geant4 Monte Carlo simulation support.
  • Dosimetric Performance: Exhibited excellent dose linearity (R² = 0.9984) up to ~11 Gy with sensitivity of 0.60 ± 0.01 nC Gy-1, and dark current below 0.1 pA. Depth-dose curves matched EBT3 and MC within 2% peak-to-plateau ratio.
  • Microdosimetric Capability: Ultra-thin active volume (~6.3 µm) achieved a low lineal energy cut-off of ~0.3 keV µm-1 (significantly lower than ~1 keV µm-1 typical for diamond microdosimeters), resolving spectra from 0.3 to 45 keV µm-1 across the Bragg peak.
  • Biological Correlation: Model-based RBE10 estimates (Loncol weighting function) ranged from ~1.1 at beam entrance to ~1.8 in the distal fall-off region, consistent with mini-TEPC results and published V79/U87 cell biological data.
  • Lateral Resolution: Detected ~800 keV proton energy variation across ±2.5 cm lateral positions—a beam achromaticity effect undetectable by dose-only measurements, highlighting the value of simultaneous microdosimetry.
  • Significance: Establishes SCD as a viable real-time, single-device alternative to TEPC reference instruments for biologically optimized treatment planning and quality assurance in proton therapy.

ParameterValueUnitContext
Proton beam energy70MeVMonoenergetic, Trento physics beamline (30° line)
Beam current10 (nominal), 50 (distal region)nAElevated at Bragg peak to improve statistics
Beam spatial profile (σ at isocenter)6.93mmGaussian pencil beam
Beam angular spread (σ)0.028°MC simulation parameter
Detector active layers2—Dosimeter + Microdosimeter in single SCD chip
Dosimeter active diameter~2.3mmDos sensitive volume
Microdosimeter active diameter~220µmµDos sensitive volume
Microdosimeter active thickness6.3µmSlab-like SV geometry
Inactive diamond substrate thickness300µmSupport layer beneath active SV
Schottky contact materialCr—50 nm thickness
Mean chord length in water20.15 ± 0.5%µmValidated via diamond-to-water conversion
Dosimeter sensitivity0.60 ± 0.01nC Gy-1Linear fit slope across ~11 Gy range
Linearity coefficient (R²)0.9984—Charge vs. dose up to ~11 Gy
Non-linearity deviation<2%Across full dose range investigated
Dark current<0.1pABeam-off leakage floor
Signal-to-dark ratioHigh—Currents from fA to tens of pA depending on depth
Lineal energy range (µDos)0.3 - 45keV µm-1From entrance to distal fall-off
Lineal energy cut-off (noise threshold)~0.3keV µm-1Significantly lower than ~1 keV µm-1 typical
Lineal energy saturation threshold65keV µm-1MCA saturation limit (high-LET secondary fragments)
Maximum proton energy deposited in SV~860keVCorresponds to y ≈ 43 keV µm-1 in water
Border effect (µDos)3.5µmInactive layer at SV edges, per Parisi et al. (2025)
Frequency-mean lineal energy (ȳF) range1 - 15keV µm-1Entrance to distal fall-off
Dose-mean lineal energy (ȳD) range~10 - 20keV µm-1Bragg peak to distal fall-off
Dose reproducibility<2%Variation across three repeated irradiations
R10 depth (DIODE)39.5 ± 0.2mm90% distal dose position
Distal dose fall-off (80-20%) DIODE0.9 ± 0.2mmSharp Bragg peak
Peak-to-plateau ratio (DIODE)4.60 ± 0.18—Matches MC (4.69) within 2%
Beam FWHM at entrance (DIODE)~18mmLateral dose profile, Gaussian fit
Beam FWHM at Bragg peak~20mmSlight broadening from MCS
Proton energy variation (lateral, ±2.5 cm)~800keVDetected only via microdosimetric data
ACQ event count~3 × 106eventsTotal over full irradiation period
ACQ time per depth600sCurrent integration window
MC events per run107primary eventsGeant4 10.08.p02
RBE10 (entrance)~1.1—Loncol weighting function
RBE10 (Bragg peak)~1.2—Loncol weighting function
RBE10 (distal fall-off)~1.8—Loncol weighting function

  1. Detector Fabrication: Single-crystal diamond (SCD) grown via MPCVD; bulk substrate (300 µm) with thin active layer (6.3 µm) patterned via Schottky Cr contacts (50 nm); encapsulated housing for front-end electronics noise suppression.
  2. Beam Exposure: 70 MeV quasi-monochromatic proton beam on Trento 30° physics beamline; detector aligned to isocenter (1.25 m from exit window) using laser-based reference.
  3. Depth Sweep Setup: Twenty-three water-equivalent (WE) depths sampled from 3.05 mm to 41.39 mm by interposing calibrated EBT3 films (each 0.355 mm WE, 3×3 cm²) in front of the detector, with denser sampling near the Bragg peak. Total in-front WE accounting included ~2.7 mm epoxy resin layer.
  4. Beam Current Selection: Nominal 10 nA for routine measurements; elevated to 50 nA for distal fall-off region to improve count statistics.
  5. Reference Detectors:
    • EBT3 Films (120-stack): Dose calibration 1-20 Gy using 30 and 70 MeV protons; analyzed 24 h post-exposure via EPSON 10000XL scanner, red channel, 169 µm resolution.
    • Giraffe MLIC: 180-layer ionization chamber array (~1.9 mm WE per channel) for depth-dose profile cross-check.
    • Mini-TEPC (LNL-INFN): Cylindrical, 1 mm diameter/height, 408 hPa propane gas simulating 1 µm tissue-equivalent path length.
  6. Data Acquisition: Simultaneous current integration (Dos) and event-by-event pulse-height recording (µDos); custom front-end charge preamplifier (µDos) and charge integrator (Dos).
  7. MC Simulation: Geant4 v10.08.p02 with Hadrontherapy toolkit; physics packages G4HadronElasticPhysicsHP, G4IonElasticPhysics, G4HadronPhysicsQGSP_BIC_HP, G4IonPhysicsPHP, and G4EmStandardPhysics_option4. Source replicated as 68.8 MeV ± 0.6 MeV Gaussian (σ = 2 mm spatial).
  8. Diamond-to-Water Conversion: Two-step iterative Geant4 simulation matching energy deposition spectra in diamond SV vs. water equivalent layer; 3.5 µm border effect applied to replicate inactive SV edges.
  9. Microdosimetric Analysis: Lineal energy y = εdep / l̄ calculated event-by-event using SV thickness as chord length; ȳF and ȳD derived per ICRU Report 98.
  10. RBE Estimation: Loncol biological weighting function r(y) applied to dose-weighted microdosimetric spectra to estimate RBE10 for clonogenic V79 cell survival.

The DIODE detector’s combined dosimetric and microdosimetric performance relies critically on the exceptional bulk purity, charge carrier mobility, and radiation hardness of single-crystal diamond (SCD). For replicating or extending this research, 6CCVD recommends:

  • Optical-Grade Single Crystal Diamond (SCD) Wafers: Required for ultra-thin active volumes (down to ~6 µm) with high charge collection efficiency. 6CCVD’s MPCVD-grown SCD is available in thicknesses from 0.1 µm to 500 µm, accommodating both the 6.3 µm µDos active layer and a robust 300 µm bulk substrate.
  • Boron-Doped Diamond (BDD) Option: For architectures requiring lateral conduction layers, guard rings, or spatial modulation of the active volume, our p-type BDD substrates can be incorporated into custom mesa or guard-ring geometries.

The DIODE architecture features two distinct Schottky contact configurations on a single SCD die: a large-area dosimeter (~2.3 mm) and a small-area microdosimeter (~220 µm). 6CCVD’s in-house capabilities directly support these and adjacent designs:

  • Custom Metalization: Our internal metallization line supports Cr, Au, Pt, Pd, Ti, W, and Cu. The Cr Schottky contact (50 nm thickness) used in the DIODE study is fully within our standard process window; we can also provide multilayer stacks (e.g., Cr/Au or Ti/Pt/Au) for hybrid wire-bonding or flip-chip integration.
  • Laser Cutting & Dicing: Circular microdosimeter SVs (~220 µm diameter) and adjacent dosimeter SVs (~2.3 mm) require sub-100 µm alignment tolerance. Our laser machining delivers ±5 µm positional accuracy, enabling monolithic multi-element detector chips.
  • Wafer Dimensions: PCD plates/wafers up to 125 mm in diameter and SCD in standard commercial dimensions (e.g., 3×3 mm², 5×5 mm², 10×10 mm², and larger) can be supplied with custom thickness profiles. Substrate thickness up to 10 mm is available for the bulk handle layer.
  • Surface Polishing: Ra < 1 nm on SCD and Ra < 5 nm on inch-size PCD ensures low-noise charge collection and supports the sub-keV µm-1 lineal energy cut-off achieved by the DIODE µDos.

Implementing a clinical-grade diamond detector system demands coordinated expertise in crystal growth, contact physics, low-noise read-out ASICs, and tissue-equivalence calibration. 6CCVD’s in-house PhD engineering team offers direct consultation on:

  • Material selection between SCD, BDD, or PCD for specific LET/RBE measurement requirements.
  • Schottky vs. ohmic contact design (Cr, Pt, or graphitic) optimized for the active volume geometry and biasing scheme.
  • Geometry optimization of SV thickness to balance signal amplitude against radiation hardness and electronic saturation thresholds—directly relevant to the ~65 keV µm-1 saturation limit observed in the DIODE study for rare high-LET secondary fragments.
  • Diamond-to-water conversion modeling based on stopping power ratios and chord-length corrections for microdosimetric spectra reconstruction.

For custom specifications or material consultation, visit 6ccvd.com or contact our engineering team directly.

View Original Abstract

Abstract Objective: This work presents the first experimental characterization of the DIODE detector, a novel detection system based on single-crystal diamond, designed for simultaneous dosimetric and microdosimetric measurements in clinical proton therapy. The aim is to evaluate its capability to measure absorbed dose, and estimate LET and RBE variations along a clinical proton beam.
 Approach: The detector was tested under a 70 MeV monoenergetic proton beam at the Trento Proton Therapy Centre. Depth-dose and lateral profiles were compared with EBT3 radiochromic films. Microdosimetric spectra were simultaneously acquired and benchmarked against a mini tissue-equivalent proportional counter (TEPC). Monte Carlo (MC) simulations were also performed to model the experimental setup and the DIODE geometry.
 Main results: The detector showed linearity with dose with a sensitivity of 0.60 ± 0.01 nC/Gy, with a dark current below 0.1 pA, ensuring a good signal-to-noise ratio. Depth-dose profiles matched EBT3 film data and MC simulations, with differences below 2% in peak-to-plateau ratios, indicating limited LET dependence.
The dose-mean lineal energy y D closely agrees with simulated dose-averaged LET values, except in the beam entrance region. In this area, y D values were lower than those obtained with the mini-TEPC due to electronic saturation limiting the detection of rare high-LET secondary fragments.
Variation in RBE was assessed from the microdosimetric data, based on Loncol’s weighting function, which refers to clonogenic cell survival. RBE values ranged from ~1.1 at the entrance to ~1.8 in the distal region, consistent with mini-TEPC data and literature RBE₁₀ values for V79 and U89 cells.
Lateral dose and microdosimetric profiles confirmed high spatial resolution and revealed proton energy variations near the Bragg peak.
 Significance: The DIODE detector demonstrated reliable performance for simultaneous dosimetric and microdosimetric characterization of clinical proton beams. Its ability to measure dose, and to support LET and RBE assessment through microdosimetric modelling, in a single device, highlights its potential as an advanced tool for beam quality assessment and biologically optimized treatment planning in proton therapy.

  1. 2003 - GEANT4—a simulation toolkit [Crossref]
  2. 2006 - Geant4 developments and applications [Crossref]
  3. 2016 - Recent developments in GEANT4 [Crossref]
  4. 2022 - Multi-arrays of 3D cylindrical microdetectors for beam characterization and microdosimetry in proton therapy [Crossref]
  5. 1998 - RBE-LET relationships for cell inactivation and mutation induced by low energy protons in V79 cells: further results at the LNL facility [Crossref]
  6. 2023a - Microdosimetry of a 62-MeV clinical proton beam with five detectors [Crossref]
  7. 2025 - First characterization of a multi-site microdosimeter [Crossref]
  8. 2021a - The effect of different lower detection thresholds in microdosimetric spectra and their mean values [Crossref]
  9. 2021b - Repeatability and reproducibility of microdosimetry with a mini-TEPC [Crossref]
  10. 2024 - Microdosimetric measurements for LET monitoring in proton therapy. The development of engineered mini-TEPCs for clinical applications: first results [Crossref]